Pfizer (NYSE: PFE) was on top of the world when it came to earnings and stock price performance. This was in early pandemic ...

Another hoped that the stock would double to $25 soon. Analyst firms remain optimistic, even as Canaccord maintained a ‘Buy’ rating while lowering its price target to $86 from $96 last week.

Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said it would cease development of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s ...

“This device represents one of the most significant advancements in Avinger’s image-guided technologies for the treatment of peripheral artery disease,” said Chief Medical Officer Jaafer Golzar.

Ocugen (OCGN) is grabbing investors’ attention with its stock climbing 195% in the past year and its modifier gene therapy platform, which promises to deliver one-time treatments that could ...

Eli Lilly & Co.’s stock jumped 6% Wednesday, after the company LLY announced positive results from a late-stage trial of its Alzheimer’s disease treatment donanemab. The Phase 3 trial showed ...